Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 12/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL286403 | 0.83 | GABRA5 (0.52) | PTGS2GABRA5PTGS1KMT2AATM | |
| SCHEMBL21834100 | 0.83 | GABRA5 (0.49) | PTGS2GABRA5PTGS1KMT2AATM | |
| SCHEMBL286512 | 0.83 | GABRA5 (0.49) | PTGS2GABRA5PTGS1KMT2AATM | |
| SCHEMBL286436 | 0.83 | PTGS1 (0.58) | PTGS2GABRA5PTGS1KMT2AALDH1A1 | |
| SCHEMBL1777407 | 0.81 | GABRA5 (0.51) | GABRA5ALDH1A1DPP4 | |
| Water SCHEMBL27477176 | 0.81 | PTGS1 (0.56) | PTGS2GABRA5PTGS1KMT2AALDH1A1 | |
| SCHEMBL3828988 | 0.81 | ALDH1A1 (0.43) | PTGS2GABRA5PTGS1ALDH1A1 | |
| SCHEMBL4790252 | 0.80 | GABRA5 (0.49) | PTGS2GABRA5ALDH1A1GABRG2GABRB3 | |
| SCHEMBL3820430 | 0.80 | GABRA5 (0.52) | GABRA5ALDH1A1 | |
| SCHEMBL3824856 | 0.78 | PTGS2 (0.57) | PTGS2PTGS1ATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231651-B1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2018-11-21 | — | — | EP | disclosed |
| EP-2767536-B1 | Isoxazolo-pyridine derivatives | HOFFMANN LA ROCHE (CH) | 2015-09-02 | — | — | EP | disclosed |
| US-9073908-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2227467-B1 | ISOXAZOLO-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-12-31 | — | — | EP | disclosed |
| US-8877782-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877783-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2014-11-04 | — | — | US | disclosed |
| US-8846719-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2767536-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2014-08-20 | — | — | EP | disclosed |
| US-20130281690-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20130274469-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130274467-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-10-17 | — | — | US | disclosed |
| US-8518974-B2 | Isoxazolo-pyridine derivatives | Hoffmann-La Roche Inc (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120184538-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-07-19 | — | — | US | disclosed |
| US-7943619-B2 | Isoxazolo-pyridazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-05-17 | — | — | US | disclosed |
| EP-2231651-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| EP-2227467-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009071476-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071477-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-11 | — | — | WO | disclosed |
| US-20090143385-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | US | disclosed |
| US-20090143371-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | ROCHE PALO ALTO LLC | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143371-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | GABRA5, GABRA1, CHRNA5 | PTGS2 3620/4885GABRA5 1/4885PTGS1 2443/4885 |
| US-20090143385-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | GABRA5, CHRNA5, GABRA1 | PTGS2 1436/4885GABRA5 1/4885PTGS1 1233/4885 |
| US-20130274467-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | GABRA5, GABRA1, GABRA4 | PTGS2 3560/4885GABRA5 1/4885PTGS1 2445/4885 |
| US-20130281690-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | GABRA5, GABRA1, GABRA4 | PTGS2 3560/4885GABRA5 1/4885PTGS1 2445/4885 |
| US-20130274469-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | GABRA5, GABRA1, GABRA4 | PTGS2 3560/4885GABRA5 1/4885PTGS1 2445/4885 |
| US-20120184538-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | GABRA5, GABRA1, GABRA4 | PTGS2 3560/4885GABRA5 1/4885PTGS1 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.